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Summary
Hypothermia is a rare but serious condition that has 
been associated with various psychiatric medications. 
We present a 76-year-old woman with refractory 
mania who developed multiple episodes of severe 
hypothermia associated with several psychiatric 
medications including olanzapine, quetiapine, valproic 
acid and oxcarbazepine. These episodes resolved 
following discontinuation of the agents. The patient 
had never experienced hypothermia before, despite 
having been on these or similar agents for many years. 
With traditional treatments for mania not feasible, 
other medications were used to treat her including 
lithium, clonazepam, gabapentin and the novel protein 
kinase c inhibitor tamoxifen. The regimen resulted 
in some success and importantly, without triggering 
hypothermia. This case alerts clinicians to the rare side 
effect of hypothermia in response to various psychiatric 
medications, the fact that patients can suddenly 
develop this intolerance and suggests possible 
medications that may be used safely without triggering 
hypothermia.
Background 
Hypothermia, a body temperature less than 
35°C/95°F, may be caused by exposure, infection, 
adrenal insufficiency, hypothyroidism, drug effects 
and lesions of the pituitary or hypothalamus, the 
primary brain regions of thermoregulation. Anti-
psychotics, both typical and atypical, and valproic 
acid (VPA) have been associated with hypothermia. 
Hypothermia from such agents is rare but is 
thought to involve mechanisms of 5-hydroxytrypt-
amine2 (5-HT2) receptors and γ-aminobutyric acid/
gaba-aminobutyric acid (GABA).1–5 
We present a 76-year-old woman with severe 
mania who had multiple episodes of severe hypo-
thermia in the setting of atypical antipsychotic, 
VPA and oxcarbazepine therapy, after years toler-
ating such medication. The authors would like to 
emphasise the importance of this rare potentially 
life-threatening adverse effect of neuroleptic-in-
duced hypothermia to all physicians, which occurs 
regardless of the duration of drug intake, to help 
them identify the condition early and treat it 
effectively.
caSe preSentation
Our patient is a 76-year-old obese (body mass index 
36.6 kg/m2) woman treated on a chronic geriatric 
psychiatry unit for 3 years for severe refractory 
mania. Medical history includes hypothyroidism, 
coronary artery disease, atrial fibrillation and hyper-
tension. Her mania is characterised by grandiose 
and paranoid delusions, aggressive and hypersexual 
behaviours. She had been treated with lithium 
300 mg/day, VPA 750 mg/day, olanzapine 5 mg/day, 
quetiapine 600 mg/day and lorazepam 1 mg pro 
re nata (PRN). Her non-psychiatric medications 
included amlodipine 2.5 mg/day, aspirin 325 mg/
day, levothyroxine 88 µg/day, loratadine 10 mg/day, 
metoprolol 25 mg/day, furosemide 20 mg/day and 
omeprazole 20 mg/day.
Five days prior to her first hypothermia, VPA 
was increased to 1000 mg/day for 1 day and then 
decreased back to 750 mg/day due to sedation. The 
day before the first hypothermia, the patient was 
started on trimethoprim/sulfamethoxazole (TMP/
SMX) for a urinary tract infection (UTI). The next 
day, the patient appeared confused. She was trans-
ferred to the local emergency room (ER), where her 
rectal temperature was found to be 33.7°C/92.7°F. 
She was admitted to the medical intensive care unit 
(MICU) for possible sepsis, started on cefepime 
and placed on a Bair Huggers to resolve the hypo-
thermia. Chest X-ray, thyroid-stimulating hormone 
(TSH), free thyroxine (free T4), complete blood 
count (CBC) and comprehensive metabolic profile 
(CMP) were normal; lithium level was 0.4 mmol/L 
(0.0–1.5 mmol/L) and total valproate levels were 
42.6 µg/mL (normal 50.0–150.0 µg/mL). Blood 
cultures were negative and there were no other 
signs indicating sepsis. By day 3, she was back at 
baseline and the medical team discontinued queti-
apine and VPA, uncertain if the hypothermia may 
have been precipitated by those medications. She 
returned to the psychiatric unit.
Two days following discontinuation of VPA 
and quetiapine, her mania worsened leading to an 
increase in olanzapine from 5 to 10 mg/day and 
finally 20 mg/day. Additionally, quetiapine and 
VPA were reintroduced at 300 mg/day and 250 mg/
day, respectively. Improvements were noted for a 
period of 1 week, before mania worsened further, 
prompting the increase of quetiapine and VPA 
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to 600 mg/day and 500 mg/day, respectively. Oxcarbazepine 
was initiated as a mood stabiliser and titrated to 600 mg/day. 
Following these changes, her temperature trended downwards 
from 36.7°C to 35.9°C and then 35.1°C (98°F–96.7°F and then 
95.2°F). Psychoactive agents were held as a standing order to 
hold psychiatric medications for temperature less than 35°C/95°F 
was in place. Olanzapine and VPA, suspected as inciting agents, 
were discontinued while other psychiatric medications were 
resumed. Urine analysis (UA) conducted at this time revealed a 
UTI which was treated with ciprofloxacin. The patient subse-
quently developed hyponatraemia requiring the discontinuation 
of oxcarbazepine.
A month following this borderline event, her mania wors-
ened. Quetiapine was increased to 800 mg/day. Gabapentin 
600 mg/day was added to help control mania. Within several 
days of these medication changes, hypothermia returned 
with a rectal temperature of 32.8°C/91°F. Psychoactive medi-
cations were held and she was transferred to the ER, where 
rectal temperature was 32.2°C/90°F. ECG, chest X-ray, 
cardiac enzymes, CMP, lactic acid, CBC with differential, 
TSH, free T4, UA and cultures obtained revealed no abnor-
malities. Lithium level was 0.7 mmol/L. Patient was warmed 
with Bair Huggers, becoming normothermic within 5 hours, 
and returned to the psychiatric unit. This was considered her 
second true hypothermia.
On return, she was restarted on 300 mg/day quetiapine 
every night and titrated over 20 days to 500 mg/day. She then 
experienced her third hypothermia with a rectal temperature of 
34.4°C/94°F. Due to this, quetiapine suspected as the inciting 
agent was subsequently discontinued.
One month following this third hypothermia, her manic 
symptoms became extreme including no sleep, aggression and 
worsening psychosis. Gabapentin was titrated to 2800 mg/day 
with some improvement in sleep but not other manic symp-
toms. VPA was now reintroduced at 250 mg/day every night 
with further titration to 500 mg/day every night. A UA at that 
time confirmed a recurrent UTI and TMP/SMX was started. 
As a precaution, discontinuing VPA was considered; however, 
her manic symptoms were so extreme that VPA was increased 
to 1000 mg/day. On the night of the increase in VPA dose, she 
became hypothermic with a rectal temperature of 34.7°C/94.5°F. 
She was transferred to the ER and treated for hypothermia with 
warming blankets. UA demonstrated the UTI had cleared (day 5 
of 7-day course of TMP/SMX). VPA level was within therapeutic 
range at 60.1 µg/mL (50.0–150.0 µg/mL). She was discharged to 
the psychiatry unit. VPA was discontinued as it was thought to 
be contributory to the hypothermia.
At this point, the team decided to exclude all agents suspected 
to induce hypothermia in the patient, explicitly VPA and all 
antipsychotics. Oxcarbazepine was excluded due to hypona-
traemia. Gabapentin dose was adjusted to a dose of 3000 mg/
day and lorazepam was replaced with clonazepam with 3 mg/
day.
Two weeks following the fourth hypothermia, she experi-
enced two further hypothermic events within a 48-hour period. 
She was on day 2 of a course of TMP/SMX for a known UTI. 
Rectal temperature was 33.5°C/92.3°F and she was transferred 
to the ER. She was placed on Bair Huggers and discharged 
back to the psychiatric unit after a confirmed rectal tempera-
ture of 36.8°C/98.3°F. Within 24 hours of being discharged, a 
rectal temperature of 35°C/95°F was noted, prompting transfer 
back to the ER. A UA conducted at this point was normal. She 
was admitted, and after return to normothermia and endocrine 
consultation discharged.
inveStigationS
All the above-mentioned UTIs were diagnosed based on posi-
tive urinalysis results reflecting elevated leucocyte esterase and 
abnormally elevated white cell counts with confirmatory cultures 
revealing Morganella morganii and Escherichia coli.
Endocrinology consult was obtained to explore other aeti-
ologies for her hypothermia. An MRI revealed no evidence of 
lesions in the pituitary or hypothalamus, regions known to be 
involved in thermoregulation. Cortisol levels and cosyntropin 
stimulation tests conducted yielded benign results, ruling out 
adrenal insufficiency as an aetiology.
treatment
The treatment team explored options for psychiatric medica-
tion given the severity of the mania and the inability to tolerate 
antipsychotics, VPA and oxcarbazepine. A clinical trial using 
tamoxifen,6 a protein kinase C (PKC) inhibitor successfully used 
in refractory mania, was reviewed and a decision made to try it. 
Clonazepam, lithium and gabapentin were continued. Lithium 
was eventually titrated up to 450 mg/day, likewise gabapentin 
was titrated up to 1500 mg/day and clonazepam to 3 mg/day.
outcome and follow-up
The patient was titrated to tamoxifen 80 mg/day (40 mg two 
times per day) without return of any hypothermia, now for 
7 months. The tamoxifen appeared to dramatically reduce the 
severity of her mania, as the other psychiatric medications had 
allowed continued aggression, hypersexual behaviours and 
marked psychosis. With the new regimen including tamoxifen, 
she generally no longer experiences aggressive or hypersexual 
behaviours and is overall pleasant. At times, she has some mood 
lability, mild paranoia or verbally inappropriate statement but 
there are days where she is noted to have a normal mental state. 
This new regimen has not precipitated any further hypothermia, 
even with subsequent UTIs. She remains in the care of the 
chronic geriatric psychiatric unit.
diScuSSion
Our patient had multiple severe hypothermias associated with 
antipsychotics, VPA and oxcarbazepine.
Case reports exist of hypothermia associated with quetiapine 
and olanzapine.7–11 In a report of data from the  WHO, atypical 
antipsychotics were more likely than other psychiatric medica-
tions to induce hypothermia, especially following initiation or 
increase in dosing, as was the case in our patient. Olanzapine 
and quetiapine were the third and fifth most common psychoac-
tive agents to cause hypothermia, and the third and fourth most 
common atypical antipsychotic agents, the most common being 
risperidone.1 van Marum et al point out several other medi-
cations reported to induce hypothermia include aripiprazole, 
ziprasidone, chlorpromazine, haloperidol and so on,1 though it 
is important to acknowledge the possibility of reporting bias.
Various mechanisms have been put forward. Antipsychotics 
with an affinity for 5-HT2 receptors are thought to have an 
association with hypothermia.1 Animal studies using N-phen-
ylpiperazine, a similar structure as aripiprazole, demonstrated 
antagonism at 5-HT2 receptors associated with their hypo-
thermic effects.4 Olanzapine is known to potently block 5-HT2A 
and 5-HT2C receptors, and has a mild selectivity for 5-HT2A 
receptors over dopamine D2 receptors.2 Quetiapine also has 
similar antagonistic effects at 5-HT2A receptors.3
Another mechanism is the interaction between antipsychotic 
agents with the neuropeptide, neurotensin (NT). Decreased levels 
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of NT may play a role in the psychopathology of schizophrenia. 
Typical antipsychotics increase synthesis of NT in the caudate 
nucleus and nucleus accumbens of dopamine terminal regions 
for the nigroneostriatal and mesolimbic systems. Atypicals such 
as olanzapine increase NT in the nucleus accumbens.12 13 NT 
plays a role in thermoregulation and in mice, stimulation with 
NT receptor agonists results in hypothermia.14
Next, we consider oxcarbazepine and VPA. A review of the 
literature revealed no cases of hypothermia associated with 
oxcarbazepine monotherapy. A single case report involving 
hypothermia in the setting of oxcarbazepine, topiramate and 
VPA multitherapy was found. In that case, the hypothermia was 
thought secondary to topiramate due to the return to normo-
thermia on topiramate’s discontinuation.15
On the other hand, VPA has numerous reports of hypothermia 
secondary to its use both with and without combination with 
antipsychotic agents, specifically pipamperone and zotepine.16–19 
In the cases of hypothermia with VPA in combination with anti-
psychotics, hypothermia resolved following discontinuation 
of the antipsychotic agents.18 19 In the cases of hypothermia 
secondary to VPA without antipsychotics, normothermia was 
regained following VPA’s discontinuation.16 17
In this case, the first hypothermia while clouded by a 
concurrent UTI, occurred in the setting of olanzapine, queti-
apine and VPA combination therapy shortly after a tempo-
rary increase in the dose of VPA. We theorise VPA may have 
potentiated the ability of the atypical agents to induce hypo-
thermia. There are reports in the literature noting increase 
in rare side effects following VPA coadministration with 
olanzapine and quetiapine, respectively.20 VPA was noted to 
increase plasma concentration of quetiapine by 77% when 
coadministered.21 An analysis on the interaction between 
VPA and olanzapine/quetiapine noted that VPA decreases 
plasma concentration of olanzapine and increases plasma 
concentration of quetiapine.20
In the fourth hypothermic event, VPA induced hypothermia 
without atypical antipsychotic agents. VPA is theorised to 
induce hypothermia via GABA.5 Stimulation of GABA recep-
tors is known to modulate thermoregulation and can induce 
hypothermia.22 The current consensus in the literature is that 
while VPA does not directly bind GABA receptors, it increases 
GABA levels, although the exact mechanism has yet to be 
elucidated.5 23 Of note, benzodiazepines interact with GABA 
receptors and induce hypothermia at high doses5; however, 
the doses in our patient were far too low to have caused 
her hypothermia. As for gabapentin, a GABA derivative, a 
review of its pharmacology states that it has no ‘appreciable 
effect’ on GABA A-receptors nor has the case been proven 
with regards to its effect on GABA B-receptor, while its effect 
on GABA turnover remains under investigation for clinical 
relevance.24
Advanced age is associated with a decline of autonomic 
nervous system function and ability to thermoregulate.25–28 
We speculate that while our patient’s age may have been a 
factor, it was not the determinant factor given the fact that 
she has had no further hypothermias in the absence of anti-
psychotics and VPA.
There are also age-related changes in drug metabolism and 
clearance. The current literature has yet to find any appreciable 
change in the metabolism or clearance of VPA with increasing 
age.29–31 There are some findings that suggest quetiapine and 
olanzapine have increased plasma concentration with advancing 
age.21 32 Such changes could increase susceptibility to hypo-
thermia following dose increases of these agents.
We also considered other drug–drug interactions, specif-
ically aspirin and VPA, as aspirin is known to increase 
VPA-free serum levels.33 While our patient took 325 mg/day 
aspirin throughout her treatment, her free serum VPA levels 
assessed on three separate occasions were all in the subther-
apeutic range (4, <3 and <3 µg/mL; normal 5–25 µg/mL), 
ruling out this as a factor.
Next, medical conditions that could potentiate hypo-
thermia were considered. Our patient has hypothyroidism, 
a medical condition known to cause hypothermia. However, 
her hypothyroidism was well controlled, normal TSH and 
free T4 levels were found repeatedly during and in-between 
episodes. Concerning environmental factors, the patient 
resided in a temperature-controlled environment and no 
other patients on the unit developed hypothermia which 
leads us to rule out this factor. Infection, another potential 
cause, was present. The first, fourth and fifth hypothermic 
events occurred with concurrent UTIs. However, no signs of 
systemic bacterial infections were found during these events. 
Additionally, the second and third hypothermic events 
occurred independent of UTIs or other infection. Lastly, 
she has had subsequent UTIs in the absence of the offending 
psychiatric medications without further hypothermia. We 
propose that UTIs may have played a role in disrupting ther-
moregulation and predisposing our patient to hypothermia 
but were not the determinant cause of her hypothermic 
events. As stated previously, primary adrenal insufficiency34 
was considered but ruled out in this case.
An MRI performed a month prior to the development of 
hypothermia revealed no evidence of lesions in the pituitary 
or hypothalamus, regions involved in thermoregulation. It is 
recognised that very small vascular lesions could have been 
present in either region without visibility on MRI, given 
the patient’s vascular risk factors. Based on this, we postu-
late that such small vascular lesions in either area could 
have caused a change in her ability to tolerate the effects 
of the psychiatric medications which she had tolerated well 
without hypothermia for many years. To our knowledge, 
there is no literature reflecting this theory but we think it is 
a possibility.
With regards to the efficacy of tamoxifen as a treatment 
modality, in the trial reviewed, while pointing out the need 
for research replication, results yielded comparable improve-
ments in mania rating to short-term trials of lithium carbonate 
and divalproex.6 Subjects who participated in that trial were 
patients with a history of difficult to manage bipolar disorder. 
The propose mechanism behind its efficacy is tamoxifen’s inhi-
bition of PKC. There is evidence that elevation in PKC activity is 
learning points
 ► Re-emphasise hypothermia as a side effect, though rare, of 
atypical antipsychotics and valproic acid.
 ► Physicians should have an increased index of suspicion for 
these neuroleptic agents as hypothermia inducers, even in 
cases where patients have used the agents for an extensive 
period without such effects prior and especially in the  
elderly.
 ► Tamoxifen, as well as lithium, gabapentin and clonazepam, 
can be an alternative treatment options for refractory mania 
in patients where means of other conventional therapy are 
non-feasible.
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present in persons with bipolar disorder and may play a role in 
some aspects of its manifestation.6
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